Advertisement

Topics

Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial ...

03:06 EDT 5 Jul 2017 | BioMedReports - Blog

— Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulatory Filings in Europe —

Read more...

Original Article: Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial ...

NEXT ARTICLE

More From BioPortfolio on "Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial ..."

Advertisement
Quick Search
Advertisement
Advertisement